JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VIR BIOTECHNOLOGY INC
Good morning, everyone. Welcome to the Jeffries Healthcare Conference 2026. For our next presentation, we have Marianne DeBakker, CEO of Weir Biotechnology. Hi, good morning, everyone. Welcome to our presentation, Weir Biotechnology, and thank you, Jeffries, for the invitation. I will be making forward-looking statements, so I refer to risks and uncertainties as described in our sec filings and also to the disclaimer which is in our corporate deck so we believe your bio is poised for significant value creation a number of reasons why first of all we have been steadily bringing in really executionally focused leadership recently with a new cfo aziz sawaf and a new cmu david lu we are really well positioned to deliver on all of our catalysts. Second, we have delivered what I would describe as once-in-a-lifetime data from our Eclipse 1 Delta pivotal trial, and I'll be talking about that, obviously, more. Third, we Have clinical validation now in our prostate cancer program, so in oncology. We have declared proof of concept for our PSMA-CD3 MOS T-cell engager. And again, more about that also later. And then finally, we have growing validation for our ProExtend masking technology platform, which is really a cornerstone of our future pipeline. And we have done a recent collaboration with Gilead on three ProEXTEND mask decent engagers for solid tumors. So strong execution, meaningful validation, and multiple upcoming catalysts positioning us really well for value creation ahead. i'll be talking first about our pivotal phase three results from eclipse one hepatitis delta trial which as i mentioned is you know truly unbelievable results but first about the disease and a bit about the commercial opportunities so if you are co-infected with both the hepatitis b virus and the hepatitus delta virus you really have very bad outlook so more than 50 percent of The patients, unfortunately, die within a period of 10 years. They progress very swiftly to cirrhosis and liver failure. Five years is the average time that it takes. So the co-infection really accelerates the whole disease progression. And then patients that are having the co infection also progress to liver cancer three times faster than patients that co-infected with hepatitis B alone. So it's the most severe form of viral hepatitis, and the estimated number of patients in the U.S. are 61,000, a little bit less than double in Europe, and in the world, about 7 million people. Unfortunately, it's a disease that has been largely underdiagnosed, and there's a couple of reasons for that. First of all, for a long period of time, actually until May of this year, there was no regimen available for patients in U.F. So it's only recently that it really makes sense to get patients tested because now they can be treated. There's a couple of levers, though, that are really pointing very positively to increased diagnosis. The first one is at a recent liver meeting, ASLD, there was a group of Delta experts that put out a paper, the Expo paper, that was suggesting that every patient that tests positive for hepatitis B should be reflex tested for hepatitus Delta. If that happens, if every single patient that gets diagnosed for hepatitis B gets tested for Delta, that would significantly increase, obviously, the testing rate and increase the diagnosis rate. And we have some good numbers from Europe. There was a couple of papers where they analyzed in Spain the effects of reflex testing, where testing went up from 8% to 93% of the B patients, and they also saw a three- to five-fold higher diagnosis. So that is a very important lever. Secondly, about a year ago, I couldn't say that, but now the testing availability in major labs like LabCorp, Quest, is available. Roche has brought out an RNA test. So everything is there now. There's no hurdle anymore to get patients tested. Technologically, it's an antibody test, it'S an RNA tests, it's not complicated, and it's available. And then thirdly, you know that GSK has recently announced approval of their BAPI treatment, which is a functional cure for a subset of B patients, and there's also more Delta regimens coming, such as ours. So that is also another impetus for more testing for hepatitis B. And the larger the funnel of patients that get tested for hepatites B, the more patients with Delta we will be able to identify. We believe this is an over-billion-dollar opportunity just, you know, because of the already identified and diagnosed patients in the U.S. and because this is a rare disease and demands, you now, orphan disease pricing. Now, about our results, again, one in a lifetime, these results were significantly better than we had hoped for. But our CLIPS-1 trial showed that after 48 weeks of treating patients with a monthly regimen of elapseron and tobevibart, we could get nearly 80% of the patients to undetectable virus. So with an RT-PCR from the blood of patients, you could no longer detect the virus. So really stunning results. and we also did some further analysis and you see that here on the right hand side in our phase two trial where we followed patients for a longer period of time and so we had 28 patients that stayed on treatment for 96 weeks and basically all of them 100% got to undetectable virus and then we did a sub-analysis of a number of patients that were really well controlled for over 96 weeks, so undetectable, we gave them the option to come off treatment and to explore whether a cure would be possible, a finite treatment. And we saw that 10 out of the 10 patients that elected to do that showed sustained viral responses, varying between 12 and 48 weeks. Early data, but sort of the early signs that we could have a curative regimen for Delta. So very promising results. We are going to get additional results from our Eclipse 2 and 3 trial in the first quarter of next year and then are planning to file mid-next year. A little bit more about our full registrational program. So I talked about Eclipse 1. Eclipse 3 is going to be looking at hep-cludex failures and really look at switching those patients over to our regimen. And then Eclipse 4 is a head-to-head trial with hep-cludex, It's really very important for payers, especially in Europe. So taken together, that will be a very comprehensive package. Now about our regimen. As is typical in virology and also what we have seen, we have compared our antibody alone with our antibody combined with an siRNA. And as in typical invirology, what you typically see is that when you combine several mechanism of actions, you get the deepest and most durable results. And that's also what we see here. So we have an SI RNA that basically dices up all the transcripts from hepatitis B and prevents hepatitis surface antigen from forming. And we have a antibody that neutralizes the delta and B virions and avoids that these viruses enter into the liver cells, into the hepatocytes. So a powerful combination, a two-pronged approach, attacking the virus in a number of different ways. It's a monthly regimen, as I mentioned, so two injections once a month. And it will be possible at launch for patients to elect to either do at-home administration themselves or go to a physician's office once a months and get their injections. The ECLIPSE-1 design is very straightforward, two-to-one randomized trial, where patients either directly get on elapsaran and to be bevibarred for 48 weeks, or they get a 12-week deferred treatment. And it's really the deferred treatment is no treatment, so it's really as if you have a placebo-controlled trial. These were the results. So on the left-hand side, you see the viral RNA, and the orange bar is sort of showing you what is typically called virologic response, so the bar is a little bit lower. You only need to see a two-log decline of RNA, but you can see that with that, we get to, you know, nearly all the patients to that level in a period of four weeks' time. And then gradually, all the patience get a virological response. But more importantly is the blue line. Do you really get rid of the virus in the patients? And you show here this gradual increase over time where you get more and more patients to undetectable. And eventually, as mentioned, at 48 weeks, we got nearly 80% of the patients through undetected RNA. On the right-hand side is ALT normalization, and also there you see this gradual increase in ALT formalization, where across sort of all the regimens that you look at at 48 weeks, you typically end up somewhere between 50 and 60 percent in the broad population of ALT normalization. Importantly, 55 percent of the patients in our trial were cirrhotics, And that is very important because what physicians typically have is that patients are already advanced to being cirrhotic by the time they see them. So we were able to show very great results in this subset of more advanced patients where 85% actually got to undetectable viral levels. So really important that our regimen works across non-cirrhotic and cirrhostic patients. and a brief moment on hepatitis b surface antigen why does it matter so hb surface antogen is obviously as the name says a protein that is on the surface of the b virus but it is because the delta virus it is a defective virus it isn't necessary for delta delta needs is to form its viral envelope and to enter into hepatocytes so what we here do with si rna component of the regimen is we dice up all the transcripts that are being formed continuously of HP surface antigen. And you see here the levels of FS surface antigen going down quite dramatically, and it's this combination, again, of an acai RNA and an antibody that allows you to show those very impressive viral efficacy results. The regimen was well tolerated, so everyone, there was no drug interruptions, there were no discontinuations, the majority of adverse events were mild to moderate in severity no serious adverse events, the most seen was a flu-like symptoms in a subset of patients and this was mostly at the first very dose that patients ever got, so the very first time they had the two injections, they had these subset of patient had these mild to mild flu-Like symptoms which were transient and resolved after 24 to 48 hours. In the next doses, these symptoms were not recurring. So this is really something at the first dose when really the regimen and the immune system gets activated. Very briefly about our Phase II finite treatment results. As mentioned, given the tremendous viral efficacy we see here for this chronic treatment, we did ask ourselves, because delta is an RNA virus, very similar to hepatitis C virus, is it also possible to potentially, you know, have a finite treatment, treat patient for a finite amount of time, and then see if they are actually cured and remain controlled. So we explored that in a small subset of patients. So as I mentioned, Patients who were 96 weeks at undetectable levels could elect to come off treatment, and 10 patients elected to do so. Seven of them were actually cirrhotics. Then we looked at what happened to their RNA levels and their ALT levels. You can see that here on the left-hand side of the slide, every single patient remained controlled and undetected. A varied time frame, some 12 weeks, some 48 weeks, but that is just because of the time the data cut was made. So all these patients are continuously being followed. And on the right-hand side, you can also see these patients were all ALT-normalized and stayed ALT normalized over time. So very early data set, but sort of the first signal that a curative regimen might be possible here for hepatitis delta. Okay, so after these great results on delta, I do want to switch gears to our oncology pipeline. So one of the most defining features that we have is a platform called ProX10. So you all know that there's a lot of T-cell engagers that are already on the market, mostly actually for liquid tumors, and they have this incredible potential of activating in vivo the T-cells that are ready to be used. They're already there to fight cancer, to fight your tumor. Unfortunately, with solid tumors, it has been very challenging because there is a lot of toxicity. There's CRS, there's ICANs. And so a lot OF the development and the progression of T-cell engagers in solid tumors has been held back by that toxicity profile. And you have to give very high levels of steroids and anti-IL-6 and whatever in order for patients to be able to tolerate the T-cel engagers. So what we have is a masking technology. you see that gray spaghetti around the T-cell engager. So what it basically does is that it forms this hydrophilic polypeptide around your T-cel engager so when the drug is given it circulates in your blood and nothing happens but when you enter the tumor microenvironment there's going to be proteases there that are going to cleave that mask off. So this entire gray mask is going to fall off and only then the T cell engager is going to get activated. The tumor binding domain is going to bind to tumor cells. The CD3 binding domain is going to bind to T cells. They're going to be brought together. And the T cells are going to be killing the tumor. So this is a very unique technology. It's a plug-and-play technology, which is really great. So for every T cell engager, we don't need to develop a new mask. We can take exactly the same mask on all of our molecules. So these are our three programs in the clinic that use this technology. One is VR5500. This is in a collaboration with Astellas being developed for prostate cancer. We just two and a half weeks ago or so received FOSTRAC designation for late-line MCRPC, and we are developing this drug in a number of different cohorts and are expecting to start pivotal trials next year. Our second drug is HER2. CD3 MOS T cell engager which is a BOSCA trial looking at efficacy across a number of different tumor types. We are looking now to look at data in more homogeneous populations as well and dose escalation is ongoing in the phase 1. And then third we have VIR5525 which is an EGFR CD3 MOS T cell engager, which is also in phase 1 and dose escalation both as monotherapy and in combination with glomerulizumab. We are going to be hosting a research event in the first quarter of next year which also will lift the veil on a number of preclinical programs that we have ongoing. Some of them using the ProX10 technology and again we entered into a Gilead deal on three ProX 10 mass T-cell engagers for solid tumors just a couple of weeks ago. Very briefly on our PSMA-targeted T-cell engager, again, this is a collaboration with Astellas. We have shown data back in February showing that we could really achieve a very great therapeutic index with, you know, great PSA 50s to 99 percentages. You see them here. PSA 99 of almost one in three patients, 29%. 45% ORR, and with a very nice safety profile, which is really what you want to show here. So most of our CRS was grade 1 or grade 2, 50% grade 1, which is significantly differentiating versus other unmasked T-cell engagers. And this was just a case example, a patient example that I showed back in February as well from a 63-year-old patient that had severe liver meds, 14 lesions in the liver, was treated with our regimen, and then nine weeks later you could see the results here on PSMA PET. And that is sort of the power of really activating a patient's own immune system to fight the cancer. That's really what you are doing here. So we were very glad to see this, and we are continuing to develop this drug in a number of different cohorts, both for late-line MCRPC and early-line MCRTC, both as a monotherapy and a combination with enzalutamide and docetaxel for early-lane MCRBC and a combination with darolutamide nubeca for hormone-sensitive prostate cancer. So that is all ongoing, and we expect clinical trials, pivotal studies, to start next year. So more to come on that program. so in conclusion we have a really very promising program for hepatitis delta with additional catalysts coming in the first quarter and then of course filing mid next year for our oncology pipeline we are going to start pivotal trials next year and of course we'll be reporting on that design in the course of 2027 and we have two additional clinical trials ongoing for HER2 and EGFR-MAS T-cell engagers in phase one. And then finally, we have a discovery engine, which is really powerful and which we will be sharing more information on in the first quarter of next year, but great validation through this collaboration on three T-cel engagers with Gilead. We are using collaborations quite strategically, as you might have seen, and we will continue to do so. So we have a platform in oncology that is so powerful that there is much more that we can do than we can ever bring forward on our own to the clinic and to market. So there will be an opportunity for further business development. And then finally, we are very well financed. So we had $901 million of cash at the end of the first quarter. And we have the cash runway into 2029. And this includes actually $90 million from an upfront payment from Gilead in the collaboration and also proceeds from our equity raise last week. So thank you for your attention. I'll be happy to take questions. Thank you. also happy not to take questions okay well thank you appreciate your interest Thank you.
- Company
- VIR BIOTECHNOLOGY INC
- Keywords
- VIR BIOTECHNOLOGY INC